COMMUNIQUÉS West-GlobeNewswire

Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer
21/02/2025
Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help clinicians support more [...]
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
21/02/2025
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who [...]
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
21/02/2025
BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]
Wellgistics Health, Inc. Announces Pricing of $4.0 Million Initial Public Offering
21/02/2025
Tampa, Florida, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and [...]
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
21/02/2025
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million , representing year-over-year [...]
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
21/02/2025
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
21/02/2025
Extends cash runway well into mid-2026; no new/replacement warrants issued KENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial [...]
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
21/02/2025
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: [...]
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
21/02/2025
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4 [...]
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
21/02/2025
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?
21/02/2025
AMSTERDAM, 21 févr. 2025 (GLOBE NEWSWIRE) -- Une nouvelle étude de Teva Pharmaceuticals Europe révèle que 46 % des médicaments génériques figurant sur la liste des médicaments essentiels de l’UE sont fournis par un seul [...]
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
21/02/2025
REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be [...]
Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards
21/02/2025
WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and innovation to radioisotope markets, was named “Researcher of the Year” at the inaugural Best [...]
Philips publishes its Annual Report 2024
21/02/2025
February 21, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2024. Philips’ Annual Report 2024 will be on the agenda of the [...]
Change to the Executive Leadership Team
21/02/2025
Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, President & [...]
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
21/02/2025
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® ( ustekinumab ) and has granted a provisional determination of [...]
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
21/02/2025
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® (ustekinumab) and has granted a provisional determination of [...]
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
21/02/2025
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® (ustekinumab) and has granted a provisional determination of [...]
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
21/02/2025
Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board Director Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger [...]

Pages